Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of veterans health administration data

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 702-709

  Santana Davila, Rafael ^a   Szabo, Aniko ^b   Arce Lara, Carlos ^a   Williams, Christina D ^c   Kelley, Michael J ^c   Whittle, Jeff ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Cisplatin; Comparative effectiveness research; Non small cell lung cancer; Outcomes research

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; GLUTAMIC ACID DERIVATIVE; GUANINE; TAXOID; VINBLASTINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COMORBIDITY; COMPARATIVE STUDY; DEHYDRATION; DRUG DOSE REGIMEN; FEMALE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; TOXICITY; VETERANS HEALTH; YOUNG ADULT; AMBULATORY CARE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; GOVERNMENT; LUNG NEOPLASMS; PATHOLOGY; REGISTER; RETROSPECTIVE STUDY; SECONDARY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES; UTILIZATION;

AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; GLUTAMATES; GUANINE; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VINBLASTINE;

EID: 84899488878     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000146     Document Type: Article

References (30)

1. Siegel R Naishadham D Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11-30.
2. Reck M Heigener DF Mok T Soria JC Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013;382:709-719.
3. Peters S Adjei AA Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol 2012; 23(Suppl 7):vii56-vii64.
4. Ettinger DS Akerley W Borghaei H et al.; National comprehensive cancer network. Non-small cell lung cancer version 2.2013. J Natl Compr Canc Netw 2013;11:645-53; quiz 653.
5. Azzoli CG Temin S Aliff T et al.; American Society of Clinical Oncology. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:3825-3831.
6. de Castria TB da Silva EM Gois AF Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013;8:CD009256.
7. Fossella F Pereira JR von Pawel J et al. Randomized multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
8. Schiller JH Harrington D Belani CP et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
9. Rosell R Gatzemeier U Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-1549.
10. Ardizzoni A Boni L Tiseo M et al.; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
11. Zhu J Sharma DB Chen AB Johnson BE Weeks JC Schrag D. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer 2013;119:2048-2060.
12. Deyo RA Cherkin DC Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
13. Klabunde CN Potosky AL Legler JM Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
14. Klabunde CN Legler JM Warren JL Baldwin LM Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast prostate colorectal and lung cancer patients. Ann Epidemiol 2007;17:584-590.
15. Anderson G Steinberg EP Whittle J Powe NR Antebi S Herbert R. Development of clinical and economic prognoses from Medicare claims data. JAMA 1990;263:967-972.
16. Sohn MW Arnold N Maynard C Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006;4:2.
17. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 2013;32:2837-2849.
18. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161.
19. Lee EW Wei LJ Amato DA et al. Survival Analysis: State of the Art. Columbus OH: Springer 1992:237-247.
20. Gayat E Resche-Rigon M Mary JY et al. Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat 2012;12:222-229.
21. Lin DY Wei L-J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-1078.
22. Hotta K Matsuo K Ueoka H Kiura K Tabata M Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
23. Paz-Ares LG de Marinis F Dediu M et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
24. Barlesi F Scherpereel A Rittmeyer A et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab cisplatin and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013;31:3004-3011.
25. Pé rol M Chouaid C Pé rol D et al. Randomized phase III study of gemcitabine or erlotinib maintenance therapy versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516-3524.
26. Bonomi P Kim K Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
27. Ferry D Billingham LJ Jarrett HW. et al. British Thoracic Oncology Group Trial BTOG2: randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax 2011; 66:A41-A41.
28. Kiely BE Stockler MR Tattersall MH. Thinking and talking about life expectancy in incurable cancer. Semin Oncol 2011;38:380-385.
29. Kiely BE Alam M Blinman P Tattersall MH Stockler MR. Estimating typical best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. Lung Cancer 2012;77:537-544.
30. Levey AS Coresh J Greene T et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.